Immune and Stromal Barriers to Active Nanoparticle Targeting of Claudin-4 in Tumors
Nanoparticles with targeting ligands can act as “magic bullets” to selectively target tumor cells, a concept that has captivated the drug delivery field for decades. Using cell culture, engineered mouse models, and spatial imaging, we studied how cellular interactions influence targeting of claudin-4 (CLDN4), a key ovarian cancer target. We coupled the C-terminal domain of Clostridium perfringens enterotoxin (cCPE), a high-affinity CLDN4 binder, to ∼60 nm dextran iron oxide nanoworms (CLIO NW) via click chemistry. Targeted NWs had nanomolar affinity for CLDN4 and specifically targeted CLDN4+ cells in culture and 3D spheroids. After systemic injection in mice, targeted NWs exhibited a long plasma half-life. In bilateral CLDN4+/CLDN4– xenograft tumors, targeted NWs accumulated more in CLDN4+ tumors but were also taken up by Kupffer cells in the liver and CD45+ immune cells in both tumors. Repeating the study with anti-CLDN4 IgG-decorated NWs, we again observed high in vitro specificity but low in vivo selectivity, as confirmed by optical and magnetic resonance imaging. Spatial proteomic analysis of tumors showed that NWs mainly accumulate in tumor cells, immune cells, and myofibroblasts, with tumor core cells mostly negative for NWs. Cell stress and metabolic profiles remain unchanged after the uptake. Coculture of CLDN4+ tumor cells and macrophages replicated the limited selectivity of targeted NWs in vivo and suggested that complement opsonization contributes to limited selectivity. Overall, stromal and immune uptake hinder CLDN4 targeting. Future efforts should focus on understanding and inhibiting nanoparticle uptake pathways to develop molecularly targeted nanomedicine.
Authors
- Jesse D. Hudspeth (ORCID: https://orcid.org/0000-0001-7557-8964)
- Tomomi M. Yamamoto (ORCID: https://orcid.org/0000-0002-6666-5406)
- Benjamin Guy Bitler (ORCID: https://orcid.org/0000-0002-5809-5271)
- Thomas J. Anchordoquy (ORCID: https://orcid.org/0000-0001-8599-4419)
- Kyle A. Sullivan (ORCID: https://orcid.org/0009-0002-7860-7948)
- Hanmant K. Gaikwad (ORCID: https://orcid.org/0000-0001-5526-0545)
- John Janetzko (ORCID: https://orcid.org/0000-0003-1604-2515)
- Gina Bouchard (ORCID: https://orcid.org/0000-0002-4155-5542)
- Kian Behbakht (ORCID: https://orcid.org/0000-0003-4793-9958)
- Elizabeth R. Woodruff (ORCID: https://orcid.org/0000-0003-0237-7453)
- Alex J. Vecchio (ORCID: https://orcid.org/0000-0002-4222-7874)
- Dmitri Simberg (ORCID: https://orcid.org/0000-0002-5288-6275)
- Aislinn Warmka
- David Angarita
- Natalie J. Serkova (ORCID: https://orcid.org/0000-0002-4573-3895)
- Hanna Mattanovich
- Khoi L.M. Nguyen
- David Siegel
- Joshua B. Judson
- Fabian Villagomez
Institutions
- University of Colorado Boulder (US)
- University of Colorado Anschutz Medical Campus (US)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- ACS Nano
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1021/acsnano.6c11570
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00